TechCrunch LA

OCTOBER 28, 2020

Saucey launched in 2014 and now operates across 22 markets including LA, San Francisco, San Diego, Sacramento, New York City, Chicago, Washington, Dallas, Orlando, Tampa and Miami. The broader cannabis market has largely struggled due to weak underlying fundamentals and poor management.

Company 188

Company Companies Los Angeles San Diego 188

TechCrunch LA

DECEMBER 8, 2020

He did note that in the four markets where the company has gone live since launching its business in January 2019 — San Diego, Los Angeles, the Inland Empire , and Sacramento — has yielded an annualized revenue run rate of over $400 million in gross merchandise value (the total value of home sales transacted on its platform).

Sales 282

Sales Demand San Diego Funding 282

socalTECH

NOVEMBER 14, 2019

San Diego-based Daasity (www.daasity.com)  which just raised $2.3M in a funding led by Orange County's Okapi Venture Capitalis looking to help direct to consumer brands use better data to direct their marketing and other efforts. So, what are you working now and where are you going next?

Startup 113

Startup Platform Commerce San Diego 113

Xconomy

JANUARY 10, 2019

The market caps of some of the most successful tech titans reach as high as $1 trillion. Yet in 2018, perceptions about these dominant companies often reflected uneasiness and doubt—and for some, so did their stock performance. Some of these platform companies, taken together, now have a shared nickname: “FAANG,” which.

Platform 43

Platform Marketing Company Companies 43

Xconomy

AUGUST 26, 2016

Critics say Mylan has been emboldened by the recall of EpiPen’s only competition last fall. Two days later, it paid AstraZeneca $550 million upfront for the rights to a group of antibiotics either already on the market or in late-stage testing. —Pfizer wasn’t done after scooping up Medivation.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

OCTOBER 28, 2016

The drug system went off the market in 2015, leaving Mylan’s EpiPen without competition and setting the stage for the furor over Mylan’s price hikes. Global Blood Therapeutics (NASDAQ: GBT ) said it has the FDA’s green light to start a trial that could produce results in 2019.

Pricing 40

Pricing Conference News Study 40